US › Healthcare

PolyPid (PYPD)

US · Healthcare · Biotechnology

$4.45+2.06%

Last close · 2026-08-04

Latest quarter · ended 2026-03-31

Revenue

Net profit

$-7.7M

Profit YoY

+6.5%

EPS

$-0.35

EPS estimate

$-0.43

EPS came in at -0.35 against a street estimate of -0.43 — a beat of 18.6%.

Key statistics

Market cap

$82.3M

Forward P/E

0.0

P/B

9.37

Book value

$0.46

EPS (TTM)

$-1.74

52-week high

$5.73

52-week low

$3.06

50-day MA

$4.76

200-day MA

$4.34

Beta

1.40

Analyst view

Analysts rate PolyPid a buy (4 buy, 0 hold, 0 sell out of 4) with an average price target of $12.00.

Shareholding

Insiders

21.23%

Institutions

34.85%

Largest institutional holders

Fund	Stake
AIGH Capital Management, LLC	8.31%
Rosalind Advisors, Inc.	3.12%
Dafna Capital Management LLC	1.08%
Morgan Stanley - Brokerage Accounts	0.92%
J. Goldman & Co LP	0.78%
ADAR1 Capital Management LLC	0.54%
Symmetry Peak Management LLC	0.45%
Citadel Advisors Llc	0.30%

See the full picture

Technicals, trade setups with a published hit rate, $AI analysis and earnings-call summaries for PolyPid — free to start.

Google Play App Store

Other Healthcare companies

Eli Lilly and Company Johnson & Johnson AbbVie Inc UnitedHealth Group Incorporated Merck & Company Inc Novartis AG ADR AstraZeneca PLC Thermo Fisher Scientific Inc Novo Nordisk A/S Amgen Inc Abbott Laboratories Gilead Sciences Inc

Data updated 2026-08-05.